Expression of the ErbB Family of Receptors in Ovarian Cancer

Abstract

Objective: To characterize the relative levels of the ErbB family of receptors and their relationship to one another in ovarian cancer.

Methods: A total of 17 serous cystadenocarcinonas were analyzed for epidermal growth factor receptor (EGF-R or ErbB-1) and ErbB-2, ErB-3, and ErbB-4 receptor expression by Western blot analysis. Receptor levels were quantified by densitometry and expressed as relative densitometry units nomalized to the level of α-tubulin. Linear regression analysis was used to analyze receptor group differences. A value of P ≤ .05 was considered statistically significant.

Results: All 17 tumors expressed detectable levels of EGF-R, ErbB-2, and ErbB-3, but ErbB-4 expression was not detected. EGF-R levels correlated with ErbB-2 (r = .70, P < .01) and ErbB-3 (r= .52, P < .05) levels. The highest correlation was obtained between the levels of ErbB-2 and ErbB-3 (r = 0.81, P < .001).

Conclusion: This study indicates an association between the levels of ErbB receptor family members in ovarian cancer. This association suggests that one or more coordinated regulatory mechanisms may be involved in determining their relative expression levels to one another.

Keywords

Ovarian cancer ErbB growth factor receptors

Get full access to this article

View all access options for this article.

References

1. Grunt TW , Huber H . The family of c-erb B genes: from basic research to clinical oncology. Oncologie 1994;17:346-357.

2. Prigent SA , Lemoine NR . The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 1992;4:1-24.

3. Khazaie K , Schirrmacher V , Lichtner RB . EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 1993;12:255-274.

4. Blechman JM , Lev S , Barg J , et al. The fourth immunoglobulin domain of the stern cell factor receptor couples ligand binding to signal transduction. Cell 1995;80:103-113.

5. Peles E , Yarden Y . Neu and its ligands: from an oncogene to neural factors. Bioessays 1993;15:815-824.

6. Wen D , Suggs SV , Karunagaran D , et al. Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol Cell Biol 1994;14:1909-1919.

7. Tzahar E , Waterman H , Chen X , et al. A hierarchical network of interreceptor interactions determines signal transduction by neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-5287.

8. Ullrich A , Schlessinger J . Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212.

9. Heldin C-H . Dimirization of cell surface receptors in signal transduction. Cell 1995;80:213-223.

10.

10. Fantl WJ , Johnson DE , Williams LT . Signaling by receptor tyrosine kinases. Annu Rev Biochem 1993;62:453-481.

11.

11. van der Geer P , Hunter T , Lindberg RA . Receptor proteintyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994;10:251-237.

12.

12. Kraus MH , Issing W , Miki T , Popescu NC , Aaronson SA . Isolation and characterization of ERBB3. a third member of the ERBB/epidermal growth factor receptor family: evidence for overeexpression in a subset of human mammary tumors. Proc Natl Acad Sci USA 1989;86:9193-9197.

13.

13. Batzer AG , Rotin D , Skolnik EY , Schlessinger J . Hierarchy of binding sites for Grb2 and Sch on the epidermal growth factor receptor. Mol Cell Biol 1994;14:5192-5201.

14.

14. Seger R , Krebs EG . The MAP kinase signaling cascade. FASEB J 1995;9:726-735.

15.

15. Earp HS , Dawson TL , Li Xiong , Yu H . Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 1995;35:115-132.

16.

16. Pinkas-Kramarski R , Soussan L , Waterman H , et al. Diversification of neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 1996;15:2452-2467.

17.

17. Soltoff SP , Carraway KL III , Prigent SA , Gullick WG , Cantley LC . ErbB3 is involved in activation of phosphatidylinositol 3-kimase by epidermal growth factor. Mol Cel Biol 1991;14:3550-3558.

18.

18. Gullick WJ . The role of the epidermal growth factor receptor and the c-erbB-2 protein in breast cancer. Int J Cancer 1990;4 (Suppl 5):55-61.

19.

19. Slamon DJ , Clark GM , Wong SG , Levin WJ , Ullrich A , McGuire WL . Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.

20.

20. Sainsbury JRC , Farndon JR , Needham GK , Malcolm AJ , Harris AL . Epidermal growth factor receptor status as predictor of early recurrence and of death from breast cancer. Lancet 1987;i:1398-1402.

21.

21. Berchuck A , Rodriguez GC , Kamel A , et al. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Corrrelation of receptor expression with prognostic factors in patients with ovarian cancer. Am J obstet Gynecol 1991;164:669-674.

22.

22. Scambia G , Panici PB , Battaglia F , et al. Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 1992;10:529-535.

23.

23. Slamon DJ , Godolphin W , Jones LA , et al. Studies of the HER/2-neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.

24.

24. Schroeder W , Biesterfeld S , Zillessen S , Rath W . epidermal growth factor receptor-immunohistochemical detection and clinical significance for treatment of primary breast cancer. Anticancer Res 1997;17:2799-2802.

25.

25. Meden H , Marx D , Raab T , Kron M , Schauer A , Kuhn W . EGF-R and overexpression of the oncogene c-erb B-2 in ovarian cancer: immunohistochemical findings and prognostic value. J Obstet Gynaecol 1995;21:167-178

26.

26. Scrov SF , Scully RE . Histological typing of ovarian tumors. International Histilogical Classification of Tumors, No. 9. Geneva: World Health Organization, 1973.

27.

27. International Federation of Gynecology and Obstetrics . Classification and staging of malignant tumors in the female pelvis. J Int Fed Gynecol 1965;3:204-204.

28.

28. Ilekis JV , Gariti J , Niederberger C , Scoccia B . Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer. Gynecol Oncol 1997;65:36-41.

29.

29. Ilekis JV , Connor JP , Prins GS , Ferrer K , Niederberger C , Scoccia B . Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 1997;66:250-254.

30.

30. Read LD , Keith D , Slamon DJ , Katzenellenbogen BS . Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines. Cancer Res 1990;50:3947-3951.

31.

31. Karlan BY , Jones J . Slamon DJ , Lagasse LD . Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial overian carcinoma cells. Gynecol Oncol 1994;53:70-77.

32.

32. Yoshihiro J . Merlino GT , Pastan I . A novel effect of EGF on mRNA stability. Nucl Acids Res 1988;16:4957-4966.

33.

33. Ewing TM , Murphy LJ , Ng M-L , et al. Regulation of epidermal growth factor receptor by progestins and glucocorticoids in human breast cancer cell lines. Int J Cancer 1989;44:744-752.

34.

34. Johnson AC . Activation of epidermal growth factor receptor gene transcription by phorbol 12-myristatge 13-acetate is mediated by activator protein 2. J Biol Chem 1996;271:3033-3038.

35.

35. Kokai Y , Myers JN , Wadat T , et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 1989;58:287-287.

36.

36. Simpson BJB , Weatherill J , Miller EP , Lessells AM , Langdon SP , Miller WR . C-erb B-3 protein expression in ovarian tumours. Br J Cancer 1995;71:758-762.

37.

37. Simpson JB , Phillips HA , Lessells AM , Landgon SP , Miller WR . c-erb B growth-factor-receptor proteins in ovarian tumours. Int J Cancer 1995;64:202-206.